Adam Bisaga

Professor of Psychiatry at CUMC · New York Presbyterian Hospital

Credentials: · · · · · · · · ·

History

Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder
National Institute on Drug Abuse · U01
Contact PI · $2.8M · New York State Psychiatric Institute Dba Research Foundation for Mental Hygiene, Inc
2020–2028
Evaluation of Safety and Pharmacokinetics of Naltrexone Implant
National Institute on Drug Abuse · UH3
Contact PI · $12.1M · New York State Psychiatric Institute Dba Research Foundation for Mental Hygiene, Inc
2018–2027
Evaluation of Safety and Pharmacokinetics of Naltrexone Implant
National Institute on Drug Abuse · UG3
Contact PI · $6.8M · New York State Psychiatric Institute Dba Research Foundation for Mental Hygiene, Inc
2018–2021
A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders
National Institute on Drug Abuse · R21
Contact PI · $423.2K · New York State Psychiatric Institute Dba Research Foundation for Mental Hygiene, Inc
2017–2020

Evaluation of the O'Neil Long Acting Naltrexone Implant in Opioid Dependent Persons
Principal investigator · Not yet recruiting · Phase 2
Go Medical Industries Pty Ltd
2026–2029
Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder
Principal investigator · Recruiting · Phase 2, Phase 3
New York State Psychiatric Institute
2023–2027
Pharmacokinetic Study of Vivitrol in Healthy Participants
Principal investigator · Completed · Phase 1
Go Medical Industries Pty Ltd
2021–2022
The O'Neil Long Acting Naltrexone Implant (OLANI) Pharmacokinetic (PK)/Safety Study in Healthy Volunteers
Principal investigator · Completed · Phase 1
Go Medical Industries Pty Ltd
2019–2021